Sun Pharma Advanced Research Shares Fall To Nearly One-Month Low On Discontinuing Psoriasis Drug

Sun Pharma ends development of SCD-044 after phase 2 trials fail to meet primary endpoints - Express Pharma

Sun Pharmaceutical Industries (along with its subsidiaries and associated companies, “Sun Pharma”) has announced top-line results from two Phase 2 clinical trials evaluating the safety and efficacy of SCD-044, an orally bioavailable sphingosine-1-phosphate (S1P) receptor 1 agonist, in the treatment of moderate to severe psoriasis and atopic dermatitis. The Phase 2 randomised, double-blind, placebo-controlled trial for moderate to severe plaque p…

Sun Pharma Advanced Research Shares Fall To Nearly One-Month Low On Discontinuing Psoriasis Drug

Shares of Sun Pharma Advanced Research fell to a nearly one-month low on Wednesday as it announced the discontinuation of the SCD-044 drug with no further plans for clinical trials.Additionally, the shares of Sun Pharma also fell as much as 1.11% on Wednesday.The research company announced results from its Phase 2 trials of the SCD-044 drug on Tuesday. Sun Pharma disclosed that the drug did not meet primary endpoints in either study and that it …